Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Riverlightning who wrote (566)	5/9/1999 6:59:00 PM
From: out_of_the_loop	Read Replies (2) \| Respond to of 5582

<<If it is the market value at the date of granting the options and they are good for 5 years, I would say they gave too much away>> I think one needs to step back and look at this situation. Who's giving what to whom? This is a fair trade. These four guys could have sold out to a big company perhaps and they went with GUMM because, I presume, their recent business relationship has gone well (in the minds of the GelTech/BioDeliveries operatives). GUMM share owners will do just fine and the makers/inventors of Zicam deserve plenty if what they have bears the test of the studies and scrutiny (of physicians, the public, and the future studies) to come. The risk of dilution is not that great because the VALUE these men bring is huge. I hearby pronounce, "it's OK with me". <LOL> I have witnessed dilution for a lot less potential relative value. This is quite the mutually beneficial relationship. Zicam may not be the only joint venture, I can postulate, so there may be even more potential value for GUMM shareholders.